Document is current
Any future updates will be listed below
-
Authors
Wolpers, Anne Caroline
Welchowski, Thomas
Sedaghat, Alexander
Wintergerst, Maximilian W. M.
Al-Kassou, Baravan
Finger, Robert P.
Terheyden, Jan Henrik
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 21 August 2023
First Online: 30 August 2023
Competing interests
: JHT: Heidelberg Engineering (Funding), Optos (Funding), Zeiss (Funding), CenterVue (Funding), Novartis (Recipient), Okko (Recipient). MWMW: Novartis Pharma GmbH: honoraria, grant; DigiSight Technologies: travel grant, D-EYE Srl: imaging devices, Heine Optotechnik GmbH: research funding, imaging devices, travel reimbursements, consultant; Eyenuk, Inc: free trial analysis; ASKIN & CO GmbH: travel reimbursement, honoraria; Berlin-Chemie AG: grant, travel reimbursements; CenterVue SpA: grant and imaging devices; Imaging devices were provided by Heidelberg Engineering, Optos, and Carl Zeiss Meditec. RPF: Bayer (Consultant), Ellex (Consultant), Novartis (Consultant), Novartis (Funding), Ophtea (Consultant), Alimera (Consultant), Santhera (Consultant), Roche/Genentech (Consultant), CentreVue (Funding), Zeiss (Funding). ACW, AS, TW and BAK declare no competing interests.
